
Semaglutide (Ozempic) improved left atrial and diastolic function in a randomized trial of patients with preserved ejection fraction heart failure (HFpEF) and obesity (via MRI) And achieved remission of symptoms in more than half of participants (2nd link) #AHA26 and @NatureMedicine nature.com/articles/s41591-0… nature.com/articles/s41591-0…
















